Please upgrade your browser.
Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced the execution of a commercialization agreement with Novartis under which Prometheus acquired exclusive rights to distribute, promote and sell PROLEUKINÂ® (aldesleukin) in the United States. Proleukin is a recombinant human interleukin-2 for treatment in adults with metastatic melanoma and metastatic kidney cancer.
In this Talkshoe.com audio podcast, Maria Coleman Filorimo and author Tracy Gray talk with Kidney Cancer Association CEO Bill Bro about their experiences in living with a child who has kidney cancer. It's a half-hour of of inspiring and frank conversation, filled with joy, tears, and love, as two moms detail their experiences in raising a girl and boy with renal cancer. Clicking the hyperlink will launch your media player.
New research by health economists at the University of York has raised concerns over any move to broaden the range of costs and economic benefits considered in the analysis of new NHS treatments.
Patient: "Forty-six thousand Canadians are diagnosed with kidney cancer a year and 16,000 will die. I know kidney cancer isn't as high profile as prostate or breast cancer, but we need access to life improving drugs."
Congress' health-care reform efforts to date have not given people confidence that the final outcome will meet goals such as greater access, affordability and quality, said Marie Gross, a Bedford health-care consultant. Subsequent reform efforts should pay greater attention to enhancing transparency and emphasizing patients' personal responsibility for their health.
Patient advocate Katherine Phillion's notes from our fall kidney cancer meeting, in Chicago.
Obesity increases the risk of developing a common and virulent form of kidney cancer, a new study finds.
Canadian patients there is no accurate count seek treatment in the United States and pay out of pocket.
|Powered by NeonCRM|